Enfortumab Vedotin Plus Pembrolizumab: Results of the EV-302 Trial With Thomas Powles, MD
18:36
Breakthrough in Bladder Cancer: FDA approval - Enfortumab Vedotin + Pelbrolizumab with Dr.Tom Powles
9:24
Panel Shares Thoughts on EV-302 Study: Response Rate, Toxicities, Progression, and More
11:58
EV-302 Patient-Reported Outcomes
8:07
Long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metast...
6:21
EV-302 Results and How They Compare to the JAVELIN Paradigm
17:18
Boost Your Bone Density with These 6 Life-Changing Tips
31:49
Building Careers in Hematology: Insights from the ASH Trainee Council
4:44